ACS Chemical Biology · 2020 · 15 citations · 22 references
PharmacyMedicinal ChemistryMolecular BiologyDrug DiscoveryMolecular PharmacologyStructure-activity RelationshipsAllosteric RecognitionAllosteric RegulationCyclin-dependent KinasesLigand BindingMolecular SimilarityReceptor-ligand InteractionsAllosteric Kinase InhibitorsCdk InhibitorsCooperative StructureCyclin-dependent Kinase InhibitorsHomologyKinase InhibitorsOrthosteric InteractionsStructural Homology
While kinases have been attractive targets to combat many diseases, including cancer, selective kinase inhibition has been challenging, because of the high degree of structural homology in the active site, where many kinase inhibitors bind. We have previously discovered that 8-anilino-1-naphthalene sulfonic acid (ANS) binds an allosteric pocket in cyclin-dependent kinase 2 (Cdk2). Here, we detail the positive cooperativity between ANS and orthosteric Cdk2 inhibitors dinaciclib and roscovitine, which increase the affinity of ANS toward Cdk2 5-fold to 10-fold, and the relatively noncooperative effects of ATP. We observe these effects using a fluorescent binding assay and heteronuclear single quantum correlation nuclear magnetic resonance (HSQC NMR), where we noticed a shift from fast exchange to slow exchange upon ANS titration in the presence of roscovitine but not with an ATP mimic. The discovery of cooperative relationships between orthosteric and allosteric kinase inhibitors could further the development of selective kinase inhibitors in general.
22
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
James Larkin, Paolo A. Ascierto, Brigitte Dréno et al. · New England Journal of Medicine · 2014 · 2K citations · Full text
Medicine, Oncology, Pharmacology +16
Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 1K citations · Full text
Medicine, Oncology, Pharmacology +11